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Abstract
Objective Pregnancies complicated by intrauterine
growth retardation (IUGR) beyond 36 weeks of gestation
are at increased risk of neonatal morbidity and mortality.
Optimal treatment in IUGR at term is highly debated.
Results from the multicenter DIGITAT (Disproportionate
Intrauterine Growth Intervention Trial At Term) trial show
that induction of labor and expectant monitoring result in
equal neonatal and maternal outcomes for comparable
cesarean section rates. We report the maternal health-
related quality of life (HR-QoL) that was measured
alongside the trial at several points in time.
Methods Both randomized and non-randomized women
were asked to participate in the HR-QoL study. Women
were asked to ﬁll out written validated questionnaires,
covering background characteristics, condition-speciﬁc
issues and the Short Form (SF-36), European Quality of
Life (EuroQoL 6D3L), Hospital Anxiety and Depression
scale (HADS), and Symptom Check List (SCL-90) at
baseline, 6 weeks postpartum and 6 months postpartum.
We compared the difference scores of all summary mea-
sures between the two management strategies by ANOVA.
A repeated measures multivariate mixed model was
deﬁned to assess the effect of the management strategies on
the physical (PCS) and mental (MCS) components of the
SF-36. Analysis was by intention to treat.
Results We analyzed data of 361 randomized and 198
non-randomized patients. There were no clinically relevant
differences between the treatments at 6 weeks or 6 months
postpartum on any summary measures; e.g., on the SF-36
(PCS: P = .09; MCS: P = .48). The PCS and the MCS
were below norm values at inclusion. The PCS improved This study is conducted for the DIGITAT study group. Other
members of the DIGITAT study group are listed in the Appendix.
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the MCS did not improve.
Conclusion In pregnancies complicated by IUGR beyond
36 weeks, induction of labor does not affect the long-term
maternal quality of life.
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Introduction
Pregnancies complicated by intrauterine growth retarda-
tion (IUGR) are at increased risk for adverse neonatal
outcome. Suspected IUGR often results in small-for-ges-
tational age (SGA) neonates, perinatal mortality and
morbidity, and adverse long-term health of the child [1–
5]. IUGR is associated with hypertensive complications in
pregnancy. Delivery to release the fetus from its nutri-
tionally inadequate environment is thought to be the only
feasible treatment [6, 7]. However, there is no consensus
regarding the optimal management strategy in IUGR at
term. Induction of labor is believed to result in a higher
chance of complications during delivery, while expectant
monitoring provides a maximal chance of spontaneous
labor at the expense of possible complications for the
child.
We recently compared induction of labor and expectant
monitoring in women with an IUGR-fetus beyond
36 weeks of gestation in a nationwide randomized clinical
equivalence trial called DIGITAT (Disproportionate
Intrauterine Growth Intervention Trial At Term; IS-
RCTN10363217). Results indicated that both treatments
result in equal neonatal and maternal outcomes [8, 9].
Alongside the DIGITAT trial, we conducted a health-
related quality of life (HR-QoL) study to examine the
impact of the non-invasive (expectant monitoring) and the
assumed invasive (induction of labor) strategy on the
mother’s self-reported health as a secondary outcome.
Given the observed clinical equivalence, maternal out-
comes gain importance to support clinical decision-
making. HR-QoL can be an important factor for women
to choose one treatment over the other and may lead to
better treatment satisfaction.
We compared the impact of the two strategies at 6 weeks
and at six moths postpartum in terms of self-reported health,
anxiety, depression, and physical and mental symptoms,
using validated questionnaires. The DIGITAT HR-QoL
study includes observational data on patient outcome from
patients refusing to participate in the trial to address poten-
tial bias from trial participation. We hypothesized that the
invasive strategy would be more burdensome, as it was
expected to be associated with a higher intervention rate
such as instrumental delivery and cesarean sections.
Methods
Patients and clinical study
In the equivalence DIGITAT trial, primary outcome was
deﬁned as a composite neonatal adverse outcome, deﬁned
as death before hospital discharge, 5-min Apgar score\7,
umbilical artery pH \7.05, or admission to the neonatal
intensive care. Eligible patients were women with a sin-
gleton pregnancy and a fetus in cephalic presentation
between 36 ? 0 and 41 ? 0 weeks gestational age, with
suspected IUGR. IUGR was deﬁned as fetal abdominal
circumference below the 10th percentile, estimated fetal
weight below the 10th percentile and/or a decreased rela-
tive growth. Exclusion criteria were maternal age below
18 years, previous cesarean section, ruptured membranes,
diabetes mellitus, renal disease, seropositivity for HIV, and
HELLP syndrome (Hemolysis Elevated Liver enzymes,
Low Platelet count) upon presentation. Women who
refused randomization were included in the study as non-
randomized patients. Details of the study design have been
described elsewhere [8, 9].
All eight academic and 44 non-academic Dutch hospitals
participated in the DIGITAT trial. The trial was approved
by the Institutional Review Board of the University of
Leiden (P170-99) and had local approval from the boards of
the other participating hospitals. Women who were eligible
for inclusion in the DIGITAT study received study infor-
mation from a research nurse, midwife, resident, or gyne-
cological staff member. Written informed consent was
obtained from all patients prior to participation. Patients
were randomly assigned to either induction of labor or
expectant management. For logistic reasons, the inclusion
for the HR-QoL study started in July 2005, 8 months after
the start of the clinical trial; the last HR-QoL patient was
included in October 2008. Individual and aggregate HR-
QoL results were not made available at any stage during the
study. Figure 1 shows a ﬂowchart of the study.
Clinical interventions and procedure
In women allocated to induction, labor was initiated within
48 h after randomization. Patients with a Bishop score[6
were induced for labor by amniotomy and, if needed,
augmented with oxytocin. Patients with a lower Bishop
score were primed with prostaglandins. In women allocated
to the expectant group, fetal condition was monitored fre-
quently during hospital or home-care admittance or in an
outpatient setting, i.e., fetal movements as reported by the
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123mother, electronic fetal heart rate monitoring, and bio-
physical proﬁle by ultrasound if indicated. Induction of
labor was recommended in case of fetal distress, i.e., non-
reassuring fetal heart rate or decreased or absent fetal
movements. Among others, reasons for induction were
prolonged rupture of membranes, pre-eclampsia, and post-
term pregnancy. The study protocol has been described in
more detail elsewhere [8, 9].
Background characteristics and clinical data (obstetric
history, medical treatment, maternal and neonatal outcome,
and interventions during hospital stay) were collected by
local research midwives or nurses using a Web-based case
record form. Data on maternal and neonatal mortality and
morbidity as well as diagnoses at discharge were collected
until 6 weeks postpartum. Outcomes of the DIGITAT trial
indicated that the medical outcomes were equivalent
between induction of labor and expectant management for
composite adverse neonatal outcomes (resp. 6.1% vs.
6.9%; 95% CI -4.9%; 3.2%) and cesarean section rate
(resp. 14.0% vs. 13.7%; 95% CI -5.0%; 5.6%) [9].
HR-QoL measures
The participating women received a folder containing
instructions, four HR-QoL questionnaires to be completed at
baseline before inclusion/randomization (B1), at baseline
after inclusion/randomization (B2), 6 weeks postpartum
(6W), and 6 months postpartum (6M). Each questionnaire
took between 10 and 30 min to complete. The women also
received four pre-stamped return envelopes, and reminder
stickers—they women could stick these stickers in their
agenda or on their calendar as a self-reminder for ﬁlling out a
questionnaire on the appropriate date. The folders, including
the questionnaires, were available in the Dutch and English
languages. Patients who did not return questionnaire 6W
within 7 weeks after delivery or questionnaire 6M within
7 monthsafterdeliveryreceivedawrittenreminderandanew
copyofthequestionnairewithapre-stampedreturnenvelope.
Questionnaire B1 contained questions on background
characteristics, e.g., date of birth, educational level, employ-
ment characteristics, household composition, obstetric history,
ethnicity, length, and weight before pregnancy. Questionnaire
6 W contained the retrospective report of pain after delivery at
days 1, 4, and 7 after delivery, using a 4-point pain intensity
scaleandan‘Idon’tknow’option.Allquestionnairesinvolved
validated measures that will be elucidated later. We have used
the Medical Outcome Study 36-Item Short Form Health Sur-
vey (SF-36; applied to questionnaires B1, 6 W, 6 M), the
European Quality of Life 6 dimensions 3 levels (EuroQoL
6D3L) with subsequent general health Visual Analogue Scale
(VAS; questionnaires B2, 6W, 6M), the Hospital Anxiety and
Depression Scale (HADS; questionnaires B2, 6W, 6M), and
the Symptom Check List (SCL-90; questionnaire 6M); all
measures have been validated in Dutch and English [10–16].
Included for HR-QoL  
N=674 (100.0%)
P Expectant n=216  P Induction n=48  RCT Induction n=192  RCT Expectant n=200 
Response n=574 
(85.2%)
P Expectant n=162 P Induction n=36  RCT Induction n=180  RCT Expectant n=181 
Participants eligible to 
DIGITAT trial n=1103 
P n=453  RCT n=650 
P Expectant n=364  P Induction n=89  RCT Induction n=321  RCT Expectant n=329 
Excluded: At inclusion 
questionnaires not 
available, n=488 
Excluded : No response, 
n=100 
Fig. 1 Flowchart. HR-QoL health-related quality of life, RTC randomized controlled trial, P treatment following protocol
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123The SF-36 is a generic questionnaire with eight health-
statussubscales:physicalfunctioning,rolelimitationsdueto
physical health problems, bodily pain, general health per-
ception, vitality, social functioning, role limitations due to
emotional health, and general mental health. The scores on
the subscales are aggregated into the standardized summary
scoresPhysical(PCS)andMentalComponentScore(MCS).
Astandardizedscoreofmean = 50andSD = 10represents
the Dutch population average [10, 11]. The EuroQoL 6D3L
is an instrument to describe general health status with six
dimensions (mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression, and cognitive functioning). An
individual’s (or population’s) health description can be
expressedinavaluebetween0(death)and 1(perfecthealth)
[12, 17]. The subsequent VAS in our study is a vertical scale
(‘thermometer’) with values 0 ‘worst possible health state’
(lower anchor) to 100 ‘best possible health state’ (upper
anchor). Patients indicated their health state by marking the
VAS, while considering the anchors [18]. The HADS is a
self-report instrument that exists of two 7-item scales: one
foranxiety andonefordepressioneach with ascorerangeof
0–21; a lower score indicating less anxiety or depression
[14, 19]. Finally, the SCL-90 is a 90-item inventory that is
used to measure the psychological symptom status. The
SCL-90 exists of one overall score and eight symptom
subscales: anxiety, agoraphobia, depression, somatic com-
plaints, insufﬁciency of acting and thinking, interpersonal
sensitivity, hostility, and sleeping problems. Higher scores
indicate worse health [16,20]. Because the SCL-90 is a long
and demanding measure, we decided to apply the SCL-90
only in the 6M questionnaire.
Analysis
If induction of labor would be more burdensome, we would
expect a differential impact of intervention strategy on the
HR-QoL measures, where induction of labor results in a
lower HR-QoL. Prior to analysis, we checked for the
presence of selective response regarding neonatal outcome,
maternal outcome, and mode of delivery; i.e., overrepre-
sentation of either very healthy or very unhealthy patients
in our sample. We deﬁned ‘adverse neonatal outcome’ as
the presence of any of the following: fetal death, 5-minute
Apgar score \7, umbilical artery pH \7.05, admission to
neonatal intensive care unit, and/or neonatal death [8, 9].
We deﬁned ‘adverse maternal outcome’ as admission to the
medium care or intensive care unit [8, 9].
Regarding short-term differences between the random-
ized induction of labor and expectant management groups,
we analyzed the retrospectively self-reported 4-point scale
pain intensity after delivery using Mann–Whitney’s U test.
Then, we compared the impact of treatment strategy
(following intention to treat) on HR-QoL for the
randomized and non-randomized groups separately on the
summary measures of the SF-36 (separate report on sub-
scales PCS and MCS), EuroQoL (mobility, self-care,
activity, pain/discomfort, anxiety/depression), VAS Gen-
eral Health, and the HADS (anxiety, depression). HR-QoL
improvement was deﬁned as the difference score between
the baseline and a postpartum measurement. The difference
scores were statistically compared between treatment
strategies using Student’s t test for each measurement
separately.
The HR-QoL impact on the SCL-90 summary scores
(anxiety, agoraphobia, depression, somatic complaints,
insufﬁciency of acting and thinking, interpersonal sensi-
tivity, hostility, and sleeping problems) at 6 moths post-
partum was addressed with Student’s unadjusted t test
between the randomized intervention strategies.
To explain the changes over time on the ‘physical’ SF-
36 PCS and the ‘mental’ SF-36 MCS scales, we applied a
repeated measures linear mixed model with the following
explanatory components: time of assessment (baseline;
6 weeks postpartum; 6 months postpartum), intervention
strategy following intention to treat (expectant; induction),
randomization (no; yes), age (B27; 28–33; C34), ethnicity
(indigenous/non-indigenous), pre-pregnancy BMI (under-
weight; normal weight; overweight), parity (nulliparous,
multiparous), educational level (lower; higher), and the
interaction terms time of assessment*randomization, and
time of assessment*intervention strategy.
Analyses were conducted using SPSS 15.0 for Windows
(SPSS Inc, Chicago, IL). A P value of\.05 (two sided) was
considered to indicate statistical signiﬁcance. We used post
hoc Bonferroni adjustment to adjust for multiple testing.
Results
Baseline characteristics
Of the 1102 participants to the DIGITAT study, 650 (56%)
were randomized, whereas 453 (44%) women participated
in the non-randomized part of the study. Not all patients
were asked for participation because of logistic reasons
because study material was not in stock in every hospital;
however, this did not lead to systematical exclusion of any
patient group to the HR-QoL study. Of the randomized
patients, 392 (60%) were asked to participate in the HR-
QoL study, versus 264 (58%) of the non-randomized
patients. Overall, 574 (85%) of the patients who were
included in the HR-QoL study responded to at least one
questionnaire (Fig. 1). Response rates were 95, 83, 72, and
59% for questionnaires B1, B2, 6W, and 6M, respectively.
Baseline characteristics of the randomized and non-
randomized HR-QoL participants and of the responding
1430 Qual Life Res (2011) 20:1427–1436
123and non-responding patients (i.e., patients who did not
respond to any questionnaire) are shown in Table 1.
We tested for selective response regarding maternal
outcome, neonatal outcome, and mode of delivery. At
6 weeks postpartum, there were no signiﬁcant differences
between responding and non-responding patients in the
proportion of composite bad neonatal outcome (14.9% vs.
10.2%; P = .052), the proportion of composite bad
maternal outcome (3.7% vs. 1.7%; P = .156), cesarean
section rates (13.1% vs. 15.1%; P = .280), and the pro-
portion of assisted vaginal delivery (11.4% vs. 8.1%;
P = .109). At 6 months postpartum, there were also no
differences between responding and non-responding
patients in the proportion of bad composite neonatal out-
come (14.4% vs. 10.4%; P = .083), the proportion of bad
composite maternal outcome (3.9% vs. 1.4%; P = .090),
cesarean section rates (13.1% vs. 15.3%; P = .251), and
the proportion of assisted delivery (10.8% vs. 8.4%;
P = .192). These results are not tabulated.
Self-reported pain after delivery
There were differences on the retrospectively self-reported
pain at days 4 (P = .006) and 7 (P = .003) after delivery
between the randomized groups in favor of induction of
labor. Figure 2 shows the pain distributions at days 1, 4,
and 7 after delivery per randomized group.
Summary measures
One-way ANOVA analyses between the average difference
scores of the two randomized groups at 6 weeks and
6 months postpartum are shown in Table 2. At 6 weeks
postpartum, only the average difference scores of the SF-36
PCS between the randomized groups were statistically,
but not clinically, different (8.99 vs. 6.49; P = .049). At
6 months postpartum, only the average differences on the
EuroQoL Pain and Discomfort domain was statistically, but
also not clinically, different between the randomized groups
(.007 vs. .031; P = .021). Mean difference scores between
the non-randomized groups did not differ signiﬁcantly
either at 6 weeks or at 6 months postpartum. After Bon-
ferroni adjustment, none of the outcomes were signiﬁcant.
Figure 3 shows the mean scores of the SF36 PCS and
MCS for the randomized groups at baseline, 6 weeks post-
partum, and 6 months postpartum. The PCS increased sub-
stantially over time between baseline and 6 weeks (PCS
scores 41.6 vs. 49.3; P = .038) and between 6 weeks and
6 monthspostpartum(49.3vs.52.2;P = .045);thePCSwas
higher than the Dutch population average at 6 months
postpartum. The MCS did not vary signiﬁcantly over time
between baseline and 6 weeks (MCS scores 47.6 vs. 47.8;
P = .559) and between 6 weeks and 6 months postpartum
(47.8vs. 48.0;P = .615).The average MCS score remained
belowtheDutchpopulationnorms(solidline)[11],andboth
Table 1 Baseline characteristics of the randomized (Rand) and non-
randomized (NRand) participants who followed induction of labor or
expectant monitoring, and the patients who did not return the HQRL
questionnaires (non-response); analyses of the randomized versus
non-randomized and responses versus non-responses
Response, N = 574 Non-response
n = 100
Randomized
versus
nonrandomized
P
Response versus
non-response
P Induction
Rand
n = 180
Expectant
Rand
n = 181
Induction
NRand
n = 36
Expectant
NRand
n = 162
Total
response
N = 574
Age: mean (SD) 28.0 (5.2) 28.0 (5.2) 31.2 (4.4) 31.8 (4.9) 29.3 (5.4) 29.5 (5.9) \.001 .680
Months to conceive:
mean (SD)
9.0 (16.7) 9.9 (18.0) 9.9 (19.1) 7.5 (10.0) 8.8 (15.3) n/a
a .355 n/a
BMI pre-pregnancy:
mean (SD)
23.3 (5.3) 23.4 (5.2) 22.3 (4.9) 22.3 (4.0) 23.0 (3.9) 22.8 (4.6) .003 .511
Dutch origin: % 89.0 86.4 90.6 84.5 87.2 59.0 .071 \.001
Has a job: % 74.9 75.0 80.6 87.8 79.2 n/a .001 n/a
Lives with partner: % 88.6 88.8 90.6 93.4 90.4 n/a .071 n/a
Nulliparious: % 58.6 58.5 51.6 61.4 59.3 57.0 .417 .369
High educational
level
b:%
15.6 18.6 25.8 43.5 25.9 18.0 \.001 .230
Smoking
c: % 45.4 38.0 24.4 25.1 32.0 37.1 \.001 .205
a These values are not available because they were asked by HR-QoL questionnaire
b Higher vocational training or university
c Did not quit smoking before the second trimester
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between 25 and 35 years old (dotted line) [21].
At 6 months postpartum, there were no HR-QoL dif-
ferences between the induction of labor and the expectant
management (randomized) groups on the SCL-90 summary
score (P = .711), or on its sub-scores anxiety (P = .756),
agoraphobia (P = .884), depression (P = .909), somatic
complaints (P = .483), insufﬁciency of acting and thinking
(P = .608), interpersonal sensitivity (P = .888), hostility
(P = .792), and sleeping problems (P = .914). These
results are not tabulated.
Multivariate mixed model
Table 3 shows the results of the multivariate mixed model
explaining the change of PCS and MCS over time, taking
some background characteristics and intervention features
into account. The b-coefﬁcients represent the change in the
dependent variable when the covariate changes with one
unit of measurement. PCS improved substantially after
childbirth (6 weeks postpartum: b = 5.84, P\.001;
6 months postpartum: b = 10.65, P\.001). The MCS did
not vary over time (6 weeks postpartum: b =- .77,
Fig. 2 In retrospect self-reported pain at days 1, 4, and 7 after delivery between the randomized induction of labor and expectant management
group
Table 2 Average HR-QoL difference scores (D) per summary measure: comparisons between randomized groups (Rand) and between non-
randomized (Nonrand) groups (Ind = induction of labor; Exp = expectant monitoring) at 6 weeks and 6 months postpartum
Summary measure D inclusion, 6 weeks
postpartum (Rand),
n = 241
D inclusion, 6 months
postpartum (Rand),
n = 198
D inclusion, 6 weeks
postpartum (Nonrand),
n = 139
D inclusion, 6 months
postpartum (Nonrand),
n = 118
Ind Exp P Ind Exp P Ind Exp P Ind Exp P
SF-36 PCS 8.99 6.49 .049 11.80 9.72 .121 4.73 6.74 .295 12.06 11.62 .832
SF-36 MCS -1.32 -1.14 .894 -.67 -.21 .784 -4.11 -1.22 .185 -3.10 .76 .086
EuroQoL mobility .017 .023 .367 .017 .033 .102 .036 .017 .191 .044 .022 .196
EuroQoL self-care .014 .010 .336 .015 .013 .536 .007 .009 .772 .007 .010 .751
EuroQoL activity .048 .047 .988 .049 .053 .727 .031 .044 .373 .048 .060 .492
EuroQoL pain/discomfort .018 .027 .356 .007 .031 .021 .015 .10 .660 .009 .009 .969
EuroQoL anxiety/depression .008 .004 .527 .006 .005 .898 .016 .011 .558 .020 .007 .336
VAS general health 1.02 2.09 .649 .64 4.17 .149 4.75 2.98 .497 8.67 4.15 .143
HADS anxiety -1.58 -1.74 .761 -1.12 -1.28 .786 -.50 -.51 .989 -.61 -.33 .740
HADS depression -1.13 -1.90 .105 -.87 -1.74 .131 -.32 -.88 .368 -.88 -.84 .962
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There was no effect of randomization (i.e., participating to
the trial as a randomized patient or a non-randomized
patient) on PCS (b =- .62, P = .493) or MCS (b = 1.09,
P = .376). Intervention according intention to treat was
not signiﬁcant on either PCS (induction of labor: b =
-1.47, P = .090) or MCS (b = .92, P = .376). Of the
background characteristics, high BMI had signiﬁcant effect
on PCS (b =- 1.47, P = .015) and age had signiﬁcant
effect on MCS (B27 years vs. 28–33 years: b = 2.71,
P = .001). None of the interaction effects were signiﬁcant
on either PCS or MCS. After post hoc Bonferroni adjust-
ment, BMI did not have signiﬁcant effect.
Discussion
We investigated the effect of induction of labor comparedto
expectant monitoring on health-related quality of life (HR-
QoL) of women with an intrauterine growth retardation
(IUGR) pregnancy beyond 36 weeks of gestation. We
found a difference in self-reported pain at day 4 and day 7
after delivery in favor of induction of labor. However, this
difference did not result in HR-QoL differences at 6 weeks
or 6 months postpartum between the treatments. We did not
ﬁnd any clinically relevant HR-QoL differences between
the randomized and non-randomized groups. The physical
and mental health as measured with SF-36 were below the
Dutch population average at inclusion. The physical health
improved over time and was above Dutch population norms
at 6 months postpartum but not above adjusted norm scores
for gender and age from the US population. Mental health
stayed under the Dutch and US norms.
Maternal HR-QoL has been deﬁned as a secondary
outcome to the DIGITAT (Disproportionate Intrauterine
Growth Intervention Trial At Term) trial [8, 9]. The clinical
outcomes of the DIGITAT trial have already shown that
induction of labor and expectant monitoring result in equal
neonatal and maternal outcomes. Cesarean section rates
were also comparable in pregnancies with IUGR beyond
36 weeks of gestation. Other results of the clinical study
showed that labor was eventually induced in 49% of the
patients in the expectant management arm of the trial, and
in the induction arm 5% of the patients had a spontaneous
start of the delivery. We have analyzed our HR-QoL data
following intention to treat so that our results have captured
the effect of initial treatment choice.
Our study has some limitations. First, the patients ﬁlled
out the questionnaires just once during pregnancy at
baseline, regardless of the period between inclusion to the
study and childbirth. Therefore, we do not know the short-
term impact of waiting, antenatal stress, and/or anxiety on
HR-QoL during the expectant management period. How-
ever, the long-term effect of waiting on HR-QoL was
probably small since the average difference of the waiting
period was not more than 10 days. Second, we have asked
women to report their pain retrospectively, which may not
have reﬂected their real perceived pain but rather their
wellbeing during their postpartum period. Further study is
needed to gain insight to prospectively self-report of pain
after the two treatment strategies. We also do not know
how the self-perceived intensity and duration of pain
developed between the 7th day and the 6th week after
delivery, as we do not have measures between those two
time points. Third, we have observed a lower response of
non-Dutch women, which may reﬂect the proportion of
women who have difﬁculties with understanding and/or
reading the Dutch or English languages. We have seen that
non-indigenous women have somewhat lower HR-QoL
scores, which indicates that the total group may have had a
lower HR-QoL score. Fourth, prior exclusion of women
with illnesses and adverse conditions to the DIGITAT trial
6 months 
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postpartum
baseline
9
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35 Waiting Induction
Physical Component Score
6 months 
postpartum
6 weeks 
postpartum
baseline
9
5
%
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I
55
50
45
40
35 Waiting Induction
Mental Component Score Fig. 3 Error bars with 95%
conﬁdence interval (CI) of the
randomized groups for
induction of labor or expectant
monitoring on the PCS and
MCS at inclusion, at 6 weeks
postpartum, and at 6 months
postpartum. The horizontal lines
indicate mean Dutch population
norm scores (solid line) and US
population norm scores for
women aged 25–34
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123may have its obvious impact on mean HR-QoL scores. Our
mean HR-QoL scores are therefore not applicable to the
total group of women with IUGR. Finally, outcomes of the
trial suggest that prior treatment preferences exist: most
(80%) of the non-randomized women were monitored
expectantly. However, the differences in the randomized
and non-randomized groups, which differed in terms of
socio-economic status, did not inﬂuence responsiveness or
the SF-36 PCS or MCS scores.
An issue that needs further investigation is the fact that
average PCS and MCS scores were lower than the popu-
lation reference norms. The mental health of the DIGITAT
patients has been low at all three measurement points. We
did not ﬁnd any systematic effect of educational level, as a
proxy of socio-economic status, on the MCS scores. Pre-
vious HR-QoL study in women after gestational hyper-
tension or preeclampsia at term randomized for induction
of labor or expectant management showed equal to popu-
lation average MCS scores at 6 weeks and 6 months
postpartum [22]. This suggests that the ﬁndings of the
DIGITAT trial are not due to general lower mental health
after childbirth. Our ﬁndings may, however, have a relation
to the mother’s concerns, uncertainty or anxiety about the
child’s health, which is in general suboptimal in the
Table 3 Multivariate mixed model with repeated measures: estimates of main and interaction effects and covariates with 95% conﬁdence
interval (CI) on the SF-36 Physical Component Score (PCS) and the Mental Component Score (MCS), N = 314
Parameter PCS MCS
Estimate (b) P 95% CI Estimate (b) P 95% CI
Intercept 43.38 \.001 40.89 to 45.86 44.53 \.001 41.55 to 47.52
Time
Baseline Ref Ref
6 weeks postpartum (6Wpp) 5.84 \.001 3.56 to 8.11 -.77 .557 -3.35 to 1.80
6 months postpartum (6Mpp) 10.65 \.001 8.38 to 12.93 1.73 .241 -1.17 to 4.62
Randomization status
Not randomized Ref Ref
Randomized -.62 .493 -2.41 to 1.16 1.09 .320 -1.07 to 3.26
Intervention following ITT
a
Expectant monitoring Ref Ref
Induction of labor -1.47 .90 -3.16 to .23 .92 .376 -1.13 to 2.97
Age
B27 years Ref Ref
28–33 years .98 .141 -.33 to 2.29 2.71 .001 1.15 to 4.28
C34 years .95 .228 -.60 to 2.50 1.54 .104 -.32 to 3.39
Parity
Nulliparous Ref Ref
Multiparous .14 .814 -1.01 to 1.28 -1.16 .096 -2.53 to .21
Indigenous (Dutch) origin
Yes Ref Ref
No -.41 .642 -2.16 to 1.33 -1.96 .066 -4.04 to .13
BMI pre-pregnancy
\18.5 (underweight) -.73 .542 -2.96 to 1.50 -.29 .830 -2.94 to 2.36
18.5–25 (normal weight) Ref Ref
[25 (overweight) -1.47 .015 -2.65 to -.28 -.34 .641 -1.76 to 1.08
Educational level
Lower Ref Ref
Higher .75 .270 -.58 to 2.07 -1.12 .167 -.47 to 2.70
Interactions
6Wpp * randomized .53 .719 -2.37 to 3.44 1.63 .330 -1.66 to 4.93
6Mpp * randomized -1.32 .372 -4.21 to 1.58 -.08 .965 -3.77 to 3.61
6Wpp * induction of labor ITT 1.75 .226 -1.08 to 4.59 -.20 .904 -3.41 to 3.01
6Mpp * induction of labor ITT 1.62 .257 -1.19 to 4.44 -.68 .709 -4.26 to 2.90
a ITT intention to treat
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123DIGITAT trial as compared to the health of the children
from the previous HR-QoL study.
We have presented the results based on the outcomes of
the randomized groups. It would also be interesting to look
at differences in HR-QoL by trial outcomes—e.g., those
with cesarean section versus those without, those with an
adverse maternal or neonatal outcome versus those with-
out. As we have insufﬁcient statistical power to make such
an analysis within DIGITAT data alone, we are planning
such an analysis together with HR-QoL data from the
HYPITAT study, a similar trial on induction of labor ver-
sus expectant management in case of hypertensive disease
at term [22].
In summary, in women with IUGR at term, maternal HR-
QoL is comparable after induction of labor or expectant
monitoring at the long term. Women report to have had less
pain after induction of labor as compared to expectant
managementintheﬁrstweekafterdelivery.Inwomenwitha
IUGRpregnancybeyond36 weeksofgestation,inductionof
labordoesnotaffectmaternalqualityoflifeonthelongterm.
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